Cargando…
The Cyclic Nitronate Route to Pharmaceutical Molecules: Synthesis of GSK’s Potent PDE4 Inhibitor as a Case Study
An efficient asymmetric synthesis of GlaxoSmithKline’s potent PDE4 inhibitor was accomplished in eight steps from a catechol-derived nitroalkene. The key intermediate (3-acyloxymethyl-substituted 1,2-oxazine) was prepared in a straightforward manner by tandem acylation/(3,3)-sigmatropic rearrangemen...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7464803/ https://www.ncbi.nlm.nih.gov/pubmed/32784502 http://dx.doi.org/10.3390/molecules25163613 |
_version_ | 1783577447386578944 |
---|---|
author | Pospelov, Evgeny V. Golovanov, Ivan S. Ioffe, Sema L. Sukhorukov, Alexey Yu. |
author_facet | Pospelov, Evgeny V. Golovanov, Ivan S. Ioffe, Sema L. Sukhorukov, Alexey Yu. |
author_sort | Pospelov, Evgeny V. |
collection | PubMed |
description | An efficient asymmetric synthesis of GlaxoSmithKline’s potent PDE4 inhibitor was accomplished in eight steps from a catechol-derived nitroalkene. The key intermediate (3-acyloxymethyl-substituted 1,2-oxazine) was prepared in a straightforward manner by tandem acylation/(3,3)-sigmatropic rearrangement of the corresponding 1,2-oxazine-N-oxide. The latter was assembled by a (4 + 2)-cycloaddition between the suitably substituted nitroalkene and vinyl ether. Facile acetal epimerization at the C-6 position in 1,2-oxazine ring was observed in the course of reduction with NaBH(3)CN in AcOH. Density functional theory (DFT) calculations suggest that the epimerization may proceed through an unusual tricyclic oxazolo(1,2)oxazinium cation formed via double anchimeric assistance from a distant acyloxy group and the nitrogen atom of the 1,2-oxazine ring. |
format | Online Article Text |
id | pubmed-7464803 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-74648032020-09-04 The Cyclic Nitronate Route to Pharmaceutical Molecules: Synthesis of GSK’s Potent PDE4 Inhibitor as a Case Study Pospelov, Evgeny V. Golovanov, Ivan S. Ioffe, Sema L. Sukhorukov, Alexey Yu. Molecules Article An efficient asymmetric synthesis of GlaxoSmithKline’s potent PDE4 inhibitor was accomplished in eight steps from a catechol-derived nitroalkene. The key intermediate (3-acyloxymethyl-substituted 1,2-oxazine) was prepared in a straightforward manner by tandem acylation/(3,3)-sigmatropic rearrangement of the corresponding 1,2-oxazine-N-oxide. The latter was assembled by a (4 + 2)-cycloaddition between the suitably substituted nitroalkene and vinyl ether. Facile acetal epimerization at the C-6 position in 1,2-oxazine ring was observed in the course of reduction with NaBH(3)CN in AcOH. Density functional theory (DFT) calculations suggest that the epimerization may proceed through an unusual tricyclic oxazolo(1,2)oxazinium cation formed via double anchimeric assistance from a distant acyloxy group and the nitrogen atom of the 1,2-oxazine ring. MDPI 2020-08-08 /pmc/articles/PMC7464803/ /pubmed/32784502 http://dx.doi.org/10.3390/molecules25163613 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Pospelov, Evgeny V. Golovanov, Ivan S. Ioffe, Sema L. Sukhorukov, Alexey Yu. The Cyclic Nitronate Route to Pharmaceutical Molecules: Synthesis of GSK’s Potent PDE4 Inhibitor as a Case Study |
title | The Cyclic Nitronate Route to Pharmaceutical Molecules: Synthesis of GSK’s Potent PDE4 Inhibitor as a Case Study |
title_full | The Cyclic Nitronate Route to Pharmaceutical Molecules: Synthesis of GSK’s Potent PDE4 Inhibitor as a Case Study |
title_fullStr | The Cyclic Nitronate Route to Pharmaceutical Molecules: Synthesis of GSK’s Potent PDE4 Inhibitor as a Case Study |
title_full_unstemmed | The Cyclic Nitronate Route to Pharmaceutical Molecules: Synthesis of GSK’s Potent PDE4 Inhibitor as a Case Study |
title_short | The Cyclic Nitronate Route to Pharmaceutical Molecules: Synthesis of GSK’s Potent PDE4 Inhibitor as a Case Study |
title_sort | cyclic nitronate route to pharmaceutical molecules: synthesis of gsk’s potent pde4 inhibitor as a case study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7464803/ https://www.ncbi.nlm.nih.gov/pubmed/32784502 http://dx.doi.org/10.3390/molecules25163613 |
work_keys_str_mv | AT pospelovevgenyv thecyclicnitronateroutetopharmaceuticalmoleculessynthesisofgskspotentpde4inhibitorasacasestudy AT golovanovivans thecyclicnitronateroutetopharmaceuticalmoleculessynthesisofgskspotentpde4inhibitorasacasestudy AT ioffesemal thecyclicnitronateroutetopharmaceuticalmoleculessynthesisofgskspotentpde4inhibitorasacasestudy AT sukhorukovalexeyyu thecyclicnitronateroutetopharmaceuticalmoleculessynthesisofgskspotentpde4inhibitorasacasestudy AT pospelovevgenyv cyclicnitronateroutetopharmaceuticalmoleculessynthesisofgskspotentpde4inhibitorasacasestudy AT golovanovivans cyclicnitronateroutetopharmaceuticalmoleculessynthesisofgskspotentpde4inhibitorasacasestudy AT ioffesemal cyclicnitronateroutetopharmaceuticalmoleculessynthesisofgskspotentpde4inhibitorasacasestudy AT sukhorukovalexeyyu cyclicnitronateroutetopharmaceuticalmoleculessynthesisofgskspotentpde4inhibitorasacasestudy |